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Abstract: Alzheimer’s disease (AD) is the most common neurodegenerative disease in the developed world. The increas-
ing life expectancy in the last years has led to an increase in the prevalence of this age-related condition and has posed an 
important medical and social challenge for developed societies. The mainstays of current therapy for AD rely on the cho-
linergic hypothesis developed more than 20 years ago. These compounds, known as acetylcholinesterase inhibitors 
(AChEIs), inhibit the cholinesterases and aim at improving the brain synaptic availability of acetylcholine. These drugs 
have been approved for the treatment of AD based on pivotal clinical trials showing modest symptomatic benefit on cog-
nitive, behavioral, and global measures. Memantine, an NMDA antagonist, has been recently included as a therapeutic op-
tion for AD. Memantine can be combined safely with AChEIs for an additional symptomatic benefit. During the last years 
our understanding of the mechanisms underlying the pathogenesis of AD has markedly expanded. Several putative neuro-
protective drugs are thoroughly investigated and many of them have reached the clinical arena. It can be anticipated that 
some of these drugs will be able to slow/prevent the progression of this condition in the near future.  
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INTRODUCTION  
Alzheimer’s disease (AD) is an age-related progressive 
neurodegenerative disorder, with onset usually in late life, 
characterized by cognitive impairment, a variety of behav-
ioral symptoms, and restrictions in activities of daily living. 
AD is the most common form of dementia and the preva-
lence increases exponentially between 65 and 85, doubling 
every 5-year age group. Demographic predictions indicate 
that the prevalence is expected to increase if new preventive 
or neuroprotective therapies do not emerge [1, 2]. Risk fac-
tors for AD include age, family history of AD, female gen-
der, lower education, cerebrovascular disease, vascular risk 
factors, prior head trauma, and presence of APOE-4 allele, 
among others. The cost of caring for patients with AD is 
extraordinary and this underlines the need for seeking new 
therapeutic approaches for this disease.  
In this review we will focus on the current pharmacologi-
cal options available in AD treatment: cholinesterase inhibi-
tors, glutamate receptor modulation, vitamin E, antioxidants, 
anti-inflammatory agents and pharmacological management 
of behavioral symptoms. In the last section we will briefly 
summarize new therapeutic approaches for AD such anti-
amyloid strategies [3, 4]. This manuscript will not cover 
other important aspects of the treatment, such as nonpharma-
cologic interventions, health maintenance activities, and 
caregiver support.  
CHOLINESTERASE INHIBITORS 
Acetylcholinesterase inhibitors (AChEIs) are the main-
stays for treating AD and have become part of standard care  
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according to the practice guidelines of the American Acad-
emy of Neurology [5]. Four AChEI drugs have been ap-
proved by the U.S. Food and Drug Administration (FDA) for 
the treatment of AD: tacrine, donepezil, rivastigmine, and 
galantamine. Tacrine is now rarely used because it has hepa-
totoxic effects in ~40 % of patients.  
The use of the current available drugs in AD relies on the 
cholinergic hypothesis developed more than 20 years ago. 
The cholinergic hypothesis states that decreased cholinergic 
transmission plays a major role in the expression of cogni-
tive, functional, and possibly behavioral symptoms in AD [6-
8]. The cholinergic hypothesis is supported by several obser-
vations that show decreases in biochemical markers of cho-
linergic function in neocortex and hippocampus that corre-
late with dementia severity [9-12]. Therefore, the hypothesis 
claims that cholinomimetic drugs can be beneficial to treat 
symptoms in AD. A limitation of the cholinergic hypothesis 
is the lack of cholinergic deficit observed in early stages of 
AD or in patients with mild cognitive impairment [13].  
Mechanism of Action of AChEIs
The general mechanism of AChEI is to increase the brain 
availability of acetylcholine (ACh) through an inhibition of 
the enzyme acetylcholinesterase (AChE). ACh is produced 
in cholinergic neurons by the action of choline acetyltrans-
ferase, concentrated in vesicles, and released from the pre-
synaptic cell following depolarization. Inhibiting AChE en-
hances cholinergic neurotransmission by prolonging the time 
ACh molecules remain in the synaptic cleft and are able to 
combine with muscarinic receptors. In mammals, two cho-
linesterases exist: AChE, which selectively hydrolyzes ACh, 
and butyrylcholinesterase, which hydrolyzes other choline 
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in humans is not completely understood. AChE has an active 
or catalytic center where the ACh is hydrolyzed releasing 
one acetic acid molecule and choline (Fig. 1). All four ap-
proved AChE drugs inhibit this process by binding to the 
catalytic site although with minor differences.  
Fig. (1). Hydrolysis of acetylcholine (ACh) by acetylcholine es-
terase.  
Cholinesterase inhibitors vary widely in their pharmacol-
ogical profiles and affinities for AChE and butyrylcholine- 
sterase. Donepezil and galantamine are 1000- and 50-fold, 
respectively, more selective for AChE than for butyrylcho-
linesterase, whereas rivastigmine inhibits both enzymes with 
similar affinity [14]. Galantamine also allosterically modu-
lates nicotinic receptors. The clinical relevance of these dif-
ferences remains unknown.  
Clinical Pharmacokinetics of AChEIs
The pharmacokinetic profile of AChEIs is summarized in 
Table 1. Donepezil has a long half-life and does not require 
coadministration with food. It is metabolized by the cyto-
chrome P450 enzymes CYP2D6 and CYP3A4 and may in-
teract with drugs that inhibit these enzymes, such as ci-
metidine, ketoconazole, paroxetine, fluoxetine, and fluvox-
amine. Galantamine exhibits 90%-100 % bioavailability and 
low protein binding potential [15]; coadministration of food 
may delay the rate of absorption but does not affect bioavail-
ability. Since galantamine is also metabolized by cytochrome 
P450s, potent inhibitors of these enzymes may increase the 
cholinergic effects of the drug, leading to adverse effects 
[15]. Under these conditions patients with AD and moderate 
hepatic dysfunction may require a reduced dosage of galan-
tamine. No dosage reduction is necessary in patients with 
renal insufficiency. Extended release capsules of galan-
tamine are also available and should be administered once 
daily. Rivastigmine has a short half-life and is coadminis-
tered with food. It has a nonhepatic metabolism, and interac-
tions are rare. A transdermal patch of rivastigmine has re-
cently been launched and shows similar efficacy to capsules 
with fewer side effects.  
Clinical Evidence Supporting the Use of AChEIs
Tacrine was the first AChEI approved by the FDA for the 
treatment of AD but it is rarely prescribed now because the 
three newer drugs are equally effective and safer [16, 17]. 
Carefully conducted clinical trials of donepezil [18-23], ri-
vastigimine [24, 25] and galantamine [26-28] all demon-
strated small but statistically significant benefits on cognitive 
and global measures relevant to dementia. The magnitude of 
the effect in pivotal clinical trials was modest, on the order 
of 2.8-4.0 point improvements on the 70-point cognitive sub-
scale of the Alzheimer’s Disease Assessment Scale (ADAS-
Cog)[29], or 1-1.5 point improvements on the 30-point Mini-
Mental Status Examination (MMSE) [30] compared to pla-
cebo over six months. Differences in global measures as-
sessed by the 7-point Clinician Interview-Based Impression 
of Change scale [31] were on the order of 0.3-0.5 points in 
patients receiving the drug compared to patients receiving 
placebo. When evaluated according to these measures, the 
three commonly used inhibitors have similar efficacy.  
Table 1.  Summary of the Pharmacokinetic Profiles of the AChEIs and NMDA Receptor Antagonist Used in AD  
Drug Bioavailability (%)  Tmax (h)   Elimination Half-Life (h)  Hepatic Metabolism  Drug Interactions 
Donepezil  
(Aricept
®)
100 3-5  60-90 CYP1A2, 
CYP2D6 
Cimetidine 
Ketoconazole 
Paroxetine 
Fluoxetine 
Fluvoxamine 
Rivastigmine 
(Exelon
®)
40 0.8-1.7  2  nonhepatic  rare 
Galantamine 
(Reminyl
®)
90-100 0.5-2  5-7  CYP2D6, 
CYP3A4 
Paroxetine 
Fluoxetine, 
Fluvoxamine 
Ketoconazole 
Erytromycin 
Memantine 
(Namenda
®)
100 3-7  60-80  nonhepatic  rare 552 Current Genomics, 2007, Vol. 8, No. 8 Alberto Lleó
AChEIs appear to have a beneficial impact on the behav-
ioral and neuropsychiatric symptoms as well, as suggested 
by a meta-analysis of well-designed clinical trials [32]. Most 
studies used the Neuropsychiatric Inventory [33] or the non-
cognitive subscale of the ADAS to assess behavioral symp-
toms; in general, patients randomized to AChEIs had small 
but statistically significant improvements compared to pla-
cebo. Although in most studies data on specific symptoms 
are unavailable, improvement has been described in halluci-
nations, distractibility, aberrant motor behavior, and apathy. 
The use of AChEIs has also been reported to reduce care-
giver burden and to delay nursing home placement [34-37].  
Although AChEIs are the current standard of care for AD 
[5], there is less agreement on how long patients should be 
treated with AChEIs. The duration in most studies has been 
6 months, and ethical considerations regarding the use of 
placebo limit the assessment of the long-term benefit of 
AChEIs in prospective studies [38]. Compared to the rate of 
decline predicted from historical untreated AD patients how-
ever, some studies have shown that the benefit may last at 
least four years [39-41]. There is no evidence on whether 
some patients respond better to one drug than another, or on 
the usefulness of switching from one AChEI to another. In 
general, switching is indicated based on side effects. Usually 
switching can be performed without a washout period, and 
interruptions longer than three weeks are not advised. There 
is no reason to combine two or more AChEIs, and this prac-
tice is not recommended.  
Safety and Tolerability of AChEIs
Overall, AChEIs are safe compounds, and side effects are 
generally limited to gastrointestinal symptoms (Table 2). 
Less common side effects include sleep disturbances or acute 
confusion, which subsides with medication withdrawal. The 
incidence of these effects can usually be minimized by initi-
ating treatment with a low dose and then escalating the dose 
slowly. The incidence of side effects is higher during initia-
tion of treatment or during the dose-escalation phases. An-
other factor that affects the incidence of side effects is drug 
absorption rate. Drugs with short half-lives, such as rivas-
tigmine and galantamine, are rapidly absorbed and may 
cause cholinergic side effects. Coadministration of either 
drug with meals delays absorption and can lower the inci-
dence of these side effects. Donepezil has a longer half-life 
and does not require coadministration with food.  
AChEIs in Clinical Practice 
The three AChEIs in current use are relatively safe, easy 
to use, and well tolerated. The benefits they offer are also 
relatively modest, representing a small but measurable symp-
tomatic improvement with no clear effect on rate of disease 
progression. Evident improvement in cognitive function is 
only observed in <10% of subjects. In counseling patients 
and caregivers on their use, it is reasonable to weigh these 
factors, along with the cost of the AChEIs. According to the 
American Academy of Neurology’s Practice Parameter evi-
dence-based review [5], AChEIs are part of standard care in 
the United States, although a careful study by an English 
consortium concluded that the one AChEI studied (donepe-
zil) was not cost-effective, as the benefits of treatment were 
below minimally relevant thresholds [42]. Patients/caregi- 
vers should understand the slight risk of nausea, vomiting or 
diarrhea (often limited to the first few days after initiating or 
increasing dose) and the likelihood that cognitive or behav-
ioral improvements will be small compared to the overall 
course of the disease.  
GLUTAMATE RECEPTOR MODULATION: ME-
MANTINE 
Another strategy to the treatment of AD is to block ab-
normal glutamatergic neurotransmission. Glutamate is the 
main excitatory neurotransmitter in the brain. One of its re-
ceptors, N-methyl-D-aspartate (NMDA), has been implicated 
in long-term potentiation, which is the neuronal mechanism 
responsible for learning and memory [43, 44]. Excessive 
glutamatergic neurotransmission leads to excitotoxity due to 
high intracellular concentrations of calcium, which causes 
neuronal dysfunction and death [45]. Memantine is a spe-
cific, low- to moderate-affinity, uncompetitive NMDA an-
tagonist that was approved in 2004 by the FDA for the 
treatment of moderate to severe AD. Preclinical pharmacol-
ogical studies suggested that memantine blocks the NMDA 
receptor and prevents calcium influx when neuronal firing 
rates are high, but leaves the calcium channel relatively open 
for neurotransmission at low stimulation rates [46]. Meman-
tine was initially developed by researchers at Eli Lilly in 
Table 2.  Management of the AChEIs and NMDA Receptor Antagonist Used to Treat Cognitive Loss in Patients with AD  
Drug  Initial Dose  Maintenance Dose  Common Side Effects  Uncommon Side Effects 
Donepezil  
(Aricept
®)
5 mg daily for 4-6 weeks  10 mg daily  nausea, diarrhea,  
vomiting 
insomnia, bad  
dreams, dizziness 
Rivastigmine 
(Exelon
®)
1.5 mg b.i.d. for 2 weeks. 
Increase 1.5 mg per dose every 2--4 weeks 
3-6 mg b.i.d.  nausea, diarrhea,  
weight loss, vomiting 
dizziness, fatigue,  
headache 
Galantamine 
(Reminyl®) 
(Reminyl ER)
4 mg b.i.d. for 4 weeks. 
Increase 4 mg per dose every 4 weeks  
(or 8 mg of the extended release formulation)
8-12 mg b.i.d.  
(or 16-24 mg of the extended 
release formulation) 
nausea, vomiting,  
diarrhea, dizziness 
Weight loss, headache,  
abdominal pain, asthenia,
somnolence 
Memantine 
(Namenda
®)
5 mg/day.  
Increase 5 mg every 2 weeks. 
10 mg b.i.d  hallucinations, confusion,
dizziness, headache 
Tiredness Current Therapeutic Options for Alzheimer’s Disease  Current Genomics, 2007, Vol. 8, No. 8    553
1963 and has been marketed in Germany and several other 
European countries since 1982 to treat a wide variety of neu-
rological syndromes and cognitive dysfunction.  
Despite the theoretical rationale for a neuroprotective 
mechanism for memantine, the studies supporting its use to 
date have demonstrated only symptomatic benefits. A 28-
week double-blind placebo-controlled trial of memantine in 
outpatients with moderate to severe AD showed better func-
tional and cognitive status in patients receiving memantine 
than in those receiving placebo [47]. The drug was well tol-
erated, and the patients on memantine did not report more 
adverse effects than those on placebo. In a separate small 12-
week multicenter double-blind randomized trial, nursing 
home patients with dementia who took 10 mg of memantine 
showed better cognitive and functional scores than those on 
placebo [48]. Another study reported that the combination of 
memantine with donepezil seemed to be superior to donepe-
zil alone in patients with moderate to severe AD [49]. This 
24-week double-blind placebo-controlled trial showed that 
patients receiving the combination therapy had superior cog-
nitive and functional scores, as assessed by the Severe Im-
pairment Battery and the Activities of Daily Living Inven-
tory, respectively. Recent trials have extended the benefit 
and safety of memantine to patients with mild AD [50]. In 
addition, the analyses of pivotal trials with memantine have 
indicated that the compound has beneficial effects on behav-
ioral symptoms, as measured by NPI [51].  
Clinical Pharmacokinetics of Memantine
Memantine is absorbed completely and has a half-life of 
60-80 h. Memantine is not metabolized by the liver and 
therefore does not inhibit cytochrome P450. The pharma-
cokinetics of memantine is not altered by food, gender, or 
age. The recommended initial dose is 5 mg/day, followed by 
an increase of 5 mg/day every week until the maintenance 
dose (10 mg twice per day) is reached (see Table 1). Like the 
AChEIs, memantine appears to offer AD patients modest 
symptomatic benefits with minimal adverse effects. In prac-
tice, given data on its potential incremental benefit in con-
junction with donepezil, it is reasonable to consider adding 
memantine when a stable AChEI regimen has been achieved.  
VITAMIN E, ANTIOXIDANTS, AND ANTI-INFLA- 
MMATORY AGENTS 
Growing evidence for the existence of oxidative stress 
and the accumulation of free radicals in the brain of AD pa-
tients [52] has led to the notion of antioxidants as a potential 
treatment. The main antioxidant strategy in AD has been 
treatment with  -tocopherol (vitamin E). The principal clini-
cal evidence comes from a double-blind randomized multi-
center trial with  -tocopherol (2000 IU/day), selegiline (10 
mg/day), both in combination, or placebo in patients with 
moderate AD [53]. The results of unadjusted comparisons 
showed no difference among the four groups after two years 
of treatment. However, when the baseline score on the 
MMSE was included as a covariate, a significant delay in the 
primary outcome was found with selegiline,  -tocopherol, 
and combination therapy. Treatment with  -tocopherol sig-
nificantly delayed institutionalization. There was no im-
provement in cognitive tests in any of the treatment groups. 
The results of this study led many physicians to recommend 
high doses of vitamin E (2000 IU/day) to their patients. 
However, some concern has emerged after a recent meta-
analysis suggested that high-dose (400 IU/day) vitamin E 
may increase all-cause mortality [54]. Excessive mortality 
was not detected in the large AD study [53], nor in a prior 
study comparing vitamin E to placebo in Parkinson’s disease 
[55]. Because of this new concern over mortality and be-
cause the putative benefits of high-dose vitamin E supple-
ments are modest, many physicians have stopped prescribing 
vitamin E supplements or prescribe <400 IU/day.  
Data from a three-year clinical trial that assessed the ef-
fects of vitamin E in patients with mild cognitive impairment 
failed to show a significant effect on slowing the progression 
to AD [56].  
Ginkgo biloba (EGb 761) is a plant extract that is widely 
used by elderly individuals and patients with dementia in 
Europe and the United States to enhance cognition. In addi-
tion to putative antioxidant properties, the extract EGb 761 
has been reported to reduce the aggregation of the amyloid- 
peptide, which is widely implicated in the pathogenesis of 
AD [57]. The extract does not improve cognition in healthy 
elderly adults [58]. A 52-week multicenter placebo-controlled 
study showed a small improvement in patients with AD (av-
erage 1.7 points in the ADAS-Cog) [59]. Although physi-
cians rarely prescribe ginkgo, it remains a popular remedy 
and is widely available in drugstores, supermarkets, and 
health food stores without a prescription. Although the effi-
cacy of ginkgo biloba in treating dementia appears very 
small, most formulations appear safe.  
Retrospective observational studies have shown that use 
of nonsteroidal anti-inflammatory drugs (NSAIDs) may have 
a protective effect against the development of AD [60-65]. In 
a meta-analysis of nine studies, the use of NSAIDs was as-
sociated with a lower risk of developing AD, and the benefit 
was greater with long-term use than with intermediate use 
[60]. However, this possible protective effect does not ex-
tend to efficacy once AD symptoms have begun; treatment 
trials in patients with established AD reported no [66-69] or 
small [70, 71] benefit. A multicenter trial in AD with r-
flurbiprofen conducted by Myriad is currently under way 
(www.clinicaltrials.gov). Currently, NSAIDs are not rec-
ommended as treatment for patients with AD.  
MANAGEMENT OF BEHAVIORAL SYMPTOMS  
A majority of patients with AD develop behavioral dis-
turbances during their illness course. These behaviors in-
clude aggression, agitation, hallucinations, delusions, sleep 
disturbances, depression, distractibility, apathy, aberrant 
motor behavior, and wandering. The presence of behavioral 
symptoms decreases the quality of life for patients and care-
givers and increases the likelihood of institutionalization. 
When possible, the first step in treatment includes evaluation 
and treatment of factors (such as pain or fever) that may have 
triggered or contributed to the symptoms. Non-pharmacolo- 
gical interventions, such as music, light exercise, or relaxa-
tion should also be considered [72]. AChEIs and memantine 
have also been shown to moderate behavioral abnormalities, 
and this effect provides another basis for their use [32]. If the 
neuropsychiatric symptoms are severe or persistent, or can-554 Current Genomics, 2007, Vol. 8, No. 8 Alberto Lleó
not be controlled by modifying the environment, specific 
medications should be considered (Table 3). 
Anxiolytic drugs are often used to alleviate restlessness, 
pacing, agitation, and aberrant motor behaviors. In general, 
the doses should be as low as possible in order to avoid ex-
cessive sedation and motor impairment.  
Depressive symptoms and major depressive episodes 
commonly occur during the course of dementia and can af-
fect up to 50% of patients with AD [73, 74]. Apathy is even 
more frequent, and it is often a diagnostic challenge to dis-
tinguish apathy from true depression. Many studies have 
tested the efficacy of antidepressants in treating the depres-
sion associated with AD yielding conflicting results. Some 
trials have shown some benefit with sertraline [73, 75], par-
oxetine, fluoxetine [76], citalopram [77, 78], imipramine 
[79], amytriptyline [76], clomipramine [80], and moclobe-
mide [81] in AD patients with depression. Others [82-84] 
have found no differences between active drug and placebo. 
Possible explanations for the divergent opinions regarding 
treatment benefits include small sample sizes in some clini-
cal trials, limited duration of treatment, different criteria and 
methods for measuring efficacy, and notable improvements 
in the placebo groups [85]. In practice, depressive symptoms 
in AD are usually treated with selective serotonin-reuptake 
inhibitors (SSRIs), beginning with low doses and increasing 
the dose based on clinical response and side effects (Table 
3). Tricyclic antidepressants have a similar efficacy but are 
used less often because most have prominent anticholinergic 
side effects, which have the potential to counteract the 
AChEI given as a treatment [76, 79].  
Antipsychotic drugs are widely used to treat neuropsy-
chiatric symptoms in AD, including delusions and hallucina-
tions, when these symptoms become disturbing to the patient 
or the family. During the last decade, the newer atypical an-
tipsychotic drugs (ie, risperidone, olanzapine, quetiapine, 
and aripiprazole, in order of introduction) have largely re-
placed the older conventional or first-generation antipsy-
chotic drugs (eg, haloperidol and thioridazine) and have been 
considered preferred treatments for these behavioral distur-
bances associated with dementia. Although antipsychotic 
drugs are widely used, few randomized trials have evaluated 
their efficacy [86]. Risperidone, haloperidol, and olanzapine 
have been shown to be effective compared to placebo in AD 
[87-91]. One randomized placebo-controlled and two small 
open-label nonrandomized trials have shown that quetiapine 
may provide some benefit in AD patients [92-94]. Quetiap-
ine did not worsen motor symptoms in patients with demen-
tia and parkinsonism [95]. A recent double-blind, placebo-
controlled trial suggested that the efficacy of atypical antip-
sychotic drugs in AD is limited by the presence of adverse 
effects [96]. There are no sufficient data on other newer 
drugs, such as sertindole, aripiprazole, zotepine, or ziprasi-
done. Two trials directly compared risperidone versus halop-
eridol; although there were no differences in global neuro-
psychiatric scores, risperidone was significantly better at 
suppressing aggressiveness [90, 97]. When medication is 
required, atypical antipsychotics are preferred because of the 
lower incidence of extrapyramidal side effects such as park-
insonism and tardive dyskinesia, compared with conven-
tional antipsychotics such as haloperidol (Table 3). A con-
cern is that the use of atypical antipsychotics has been asso-
ciated with an increased risk of adverse cerebrovascular 
events and death. A recent meta-analysis of 15 placebo-
controlled studies (9 unpublished) suggested that the use of 
antipsychotics was associated with small increased risk for 
death (OR = 1.54) compared with placebo [98, 99]. It is im-
portant to mention that no individual drug is responsible for 
the effect, and it is only when all trials are combined that a 
significant effect is found. In practice, the use of antipsy-
Table 3.  Summary of the Main Agents Used to Treat Neuropsychiatric Symptoms of AD  
Type and Drug  Initial Dose   Maintenance Dose   Targeted Symptoms 
Atypical antipsychotics 
 Risperidone 
 Olanzapine 
 Quetiapine 
 Ziprasidone 
0.5 mg  
2.5 mg  
25 mg  
20 mg  
0.75-2 mg/day 
5-10 mg/day 
100-300 mg/day 
40-160 mg/day 
psychosis and agitation 
Traditional neuroleptic 
 Haloperidol   0.25 mg  1-3 mg/day  psychosis and agitation 
Selective serotonin-reuptake inhibitors 
 Fluoxetine 
 Sertraline  
 Paroxetine 
 Citalopram 
 Escitalopram  
5 mg 
25 mg 
10 mg 
10 mg  
5 mg  
10-40 mg/day 
75-100 mg/day 
10-40 mg/day 
10-20 mg/day 
20-40 mg/day 
depression, anxiety, agitation 
Anxiolytics 
 Diazepam  
 Alprazolam 
 Lorazepam 
2.5 mg 
0.5 mg 
0.5 mg  
2.5-10 mg/day 
0.5-2 mg/day 
0.5-2 mg/day 
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chotics should be prescribed with care in patients with de-
mentia, in low doses and rapidly discontinued when symp-
toms resolve.  
FUTURE PERSPECTIVES  
Molecular mechanisms of AD are increasingly well un-
derstood. There is growing consensus that generation of A
oligomers is a key event in the pathogenesis of AD and initi-
ate a cascade of events eventually leading to synaptic and 
neuronal dysfunction. Just as the cholinergic hypothesis of 
memory loss guided drug development that eventually led to 
the introduction of AChEIs, drug discovery programs guided 
by the amyloid hypothesis hold the promise of discovering 
compounds that will alter the underlying pathophysiology of 
the AD process.  
The two main approaches to anti-amyloid therapy have 
been to reduce the production or to increase the clearance of 
A42 [100]. The goal of A reduction has centered on a 
search for molecules that inhibit - and -secretase. The 
search for -secretase inhibitors has yielded several potent 
compounds that inhibit -secretase in cell lines and dramati-
cally lower A levels in blood, cerebrospinal fluid, and brain 
[101]. Enthusiasm for developing -secretase inhibitors has 
now cooled somewhat, since -secretase also process other 
substrates, including the Notch receptor [102] involved in 
critical pathways. Indeed, in vivo treatment with a -secretase 
inhibitor reduced A production but also caused profound 
alterations in thymocyte differentiation and other Notch-
dependent processes [103]. A few small clinical trials using 
-secretase inhibitors have been conducted, and the com-
pounds decreased A in plasma but not in the cerebrospinal 
fluid [104]. -secretase [105, 106], is another potential target 
for drug development [107, 108]. Clinical data support this 
line of drug development, as -secretase activity in human 
brain increases with age [109]. Developing a -secretase 
inhibitor, however, has proved challenging, and none has 
been tested extensively in humans.  
The main approach to induce A clearance has been anti-
amyloid immunotherapy. Since the surprising discovery that 
immunization with A42 prevented the appearance of amy-
loid pathology in a transgenic mouse model of AD [110], 
other studies have reproduced the results using different 
models [111, 112]. Passive immunization with antibodies 
against human A also decreased A in transgenic mice and 
improved performance in test behaviors [113, 114]. Based on 
these preclinical findings, a multicenter randomized double-
blind placebo-controlled Phase II trial was organized to test 
the safety and efficacy of active A42 immunization in hu-
mans. The immunization trial was halted after the second 
injection because 6% of patients who received the active 
immunization developed meningoencephalitis [115]. Al-
though this initial trial did not proceed as smoothly as antici-
pated, the trial yielded important findings that validate the 
immunological approach to treat AD. Neuropathological 
evaluation of immunized cases showed areas with unusually 
reduced amyloid burden and evidence of A-associated mi-
croglia, suggesting that the immunization had increased A
clearance by activated microglia [116, 117]. Based on these 
observations, Elan and other companies have launched new 
trials that are currently ongoing with passive or safer active 
immunization in patients with AD.  
Another approach to stimulate A clearance is to develop 
compounds that bind to A. One example, is tramiprosate, 
an antifibrillization agent tested in AD. Although in the 
phase II study the drug was shown to be safe and was able to 
lower A42 levels in CSF, the phase III study was halted due 
to lack of efficacy [118].  
CONCLUSIONS 
AChEIs and memantine are the main available agents 
prescribed for treating the cognitive symptoms in AD. These 
drugs produce modest symptomatic benefit on cognitive, 
behavioral and functional symptoms with minimal impact on 
the disease process. AChEIs can be combined safely with 
memantine for an additional symptomatic benefit. Several 
putative neuroprotective drugs are thoroughly investigated, 
and the development of interventions that substantially delay 
the onset or modify the progression of Alzheimer’s disease 
can be anticipated. 
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